FDA General

Abrysvo and Arexvy labels will caution about risk of rare neurologic disorder

Guidance could reduce lead exposure by about 20% to 30%

Agency recommends conducting larger studies with more patients from different racial groups

FDA boxed warning led to multiple studies on the issue in 2024

Agency also warns about Daye's vaginal microbiome screening kit

Several nominees may pose a threat to evidence-based public health

Most device records did not include information about performance testing in different skin tones

Macitentan/tadalafil and sotatercept approvals shifted the field, but by how much seems to differ

Research should be interpreted cautiously, says researcher

Proposal comes after years of lawsuits alleging links between talc-based baby powder and cancer

What does the future hold in the wake of recent foodborne fiascos?

A look at the agency's recent moves on a leading decongestant

Generic liraglutide approved at dosage for type 2 diabetes only

Tirzepatide ok'd for obstructive sleep apnea in people with obesity